Inhibition of ovarian cancer cell proliferation by Pien Tze Huang via the AKT-mTOR pathway

Oncology Letters

Volumn 7, Issue 6, 2014, Pages 2047-2052

  He, Fan ^a   Wu, Hui Ni ^b   Cai, Mu Yan ^c   Li, Chang Peng ^c   Zhang, Xin ^d   Wan, Quan ^e   Tang, Shuang Bo ^a   Cheng, Jian Ding ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b School of Public Health   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cell cycle; Ovarian cancer; Pien Tze Huang; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; HERBACEOUS AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PIEN TZE HUANG; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASSAY; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MTT ASSAY; OVARY CANCER; PROTEIN EXPRESSION; TRANSWELL ASSAY; WESTERN BLOTTING; WOUND HEALING;

EID: 84898888348     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1989     Document Type: Article

References (28)

1. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
2. Angioli R, Palaia I, Zullo MA, et al: Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol 100: 455-461, 2006.
3. Chan JY, Cheung JY, Luk SC, Wu YJ, Pang SF and Fung KP: Anti-cancer and pro-apoptotic effects of an herbal medicine and Saccharomyces cerevisiae product (CKBM) on human hepatocellular carcinoma HepG2 cells in vitro and in vivo. Immunopharmacol Immunotoxicol 26: 597-609, 2004.
4. Lee HJ, Lee EO, Rhee YH, et al: An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis. Carcinogenesis 27: 2455-2463, 2006.
5. Kumagai T, Müller CI, Desmond JC, Imai Y, Heber D and Koeffler HP: Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines. Leuk Res 31: 523-530, 2007.
6. Sha O, Niu J, Ng TB, Cho EY, Fu X and Jiang W: Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review. Cancer Chemother Pharmacol 71: 1387-1393, 2013.
7. Lee KK, Kwong WH, Chau FT, Yew DT and Chan WY: Pien Tze Huang protects the liver against carbon tetrachloride-induced damage. Pharmacol Toxicol 91: 185-192, 2002.
8. Lin JM, Wei LH, Chen YQ, et al: Pien Tze Huang induced apoptosis in human colon cancer HT-29 cells is associated with regulation of the Bcl-2 family and activation of caspase 3. Chin J Integr Med 17: 685-690, 2011.
9. Zhuang Q, Hong F, Shen A, et al: Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model. Int J Oncol 40: 1569-1574, 2012.
10. Shen AL, Hong F, Liu LY, et al: Effects of Pien Tze Huang on angiogenesis in vivo and in vitro. Chin J Integr Med 18: 431-436, 2012.
11. Kigawa J: New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Med 56: 43-50, 2013.
12. Li X, Yang G, Li X, et al: Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in chinese. PLoS One 8: e60338, 2013.
13. Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007.
14. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
15. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G and Kozma SC: Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17: 6649-6659, 1998.
16. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC and Thomas G: Drosophila S6 kinase: a regulator of cell size. Science 285: 2126-2129, 1999.
17. Oldham S, Montagne J, Radimerski T, Thomas G and Hafen E: Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev 14: 2689-2694, 2000.
18. Zhang H, Stallock JP, Ng JC, Reinhard C and Neufeld TP: Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev 14: 2712-2724, 2000.
19. Fingar DC and Blenis J: Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004.
20. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
21. Yang Q and Guan KL: Expanding mTOR signaling. Cell Res 17: 666-681, 2007.
22. Bhutani J, Sheikh A, Niazi AK: Akt inhibitors: mechanism of action and implications for anticancer therapeutics. Infect Agent Cancer 8: 49, 2013.
23. Madan E, Gogna R, Bhatt M, Pati U, Kuppusamy P and Mahdi AA: Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget 2: 948-957, 2011.
24. Marx J: Oncology. Recruiting the cell's own guardian for cancer therapy. Science 315: 1211-1213, 2007.
25. Bartek J and Lukas J: Mammalian G1-and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol 13: 738-747, 2001.
26. Hedberg Y, Ljungberg B, Roos G and Landberg G: Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 88: 1417-1423, 2003.
27. Baker SJ and Reddy EP: CDK4: A key player in the cell cycle, development, and cancer. Genes Cancer 3: 658-669, 2012.
28. Hleb M, Murphy S, Wagner EF, et al: Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes. J Biol Chem 279: 31948-31955, 2004.